

Summary of achievements for each of the awards and recognitions:

ELECTED FELLOW OF NATIONAL SCIENCE ACADEMIES

- 1. Elected as Fellow of National Academy of Medical Sciences (FAMS) (2017)**
- 2. Elected as Fellow of National Academy of Sciences, India (FNASc.) (2019)**
- 3. Elected as Fellow of Indian Academy of Sciences (FASc.), Bengaluru (2020)**
- 4. Elected as Fellow of Indian National Science Academy (INSA), New Delhi (2023)**

These prestigious fellowships recognize Dr. Bal's significant contributions to science and research in India. FAMS, FNASc., FASc., and FNA marks a major recognition of an individual's scientific excellence in his/her own field of research.

Society of Nuclear Medicine Awards

- 1. 2022 Dr. Henry N. Wagner, Jr., MD, Best International Abstract of the Year:**
- 2. 2021 Dr. Henry N. Wagner, Jr., MD, Best Abstract of the Year:**

Awarded for exceptional research presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meetings, the USA and Canada. Two consecutive years getting this award at an international level where more than 15,000 abstracts are screened each year. The recognition underscores ground-breaking work in nuclear medicine therapeutics. As a consequence, ²²⁵Actinium-based alpha-ceuticals have made great stride in last 3-4 years in western world which started in India by an investigator initiated project funded by ICMR (Sanction No.5/13/2/CSB/ICRC/2020NCD3 – PI Dr. Bal).

3. **SNMMI Best Researcher Award in Nuclear Medicine Therapy (2019):** This prestigious award from the Society of Nuclear Medicine and Molecular Imaging, Therapy Council, honors exceptional research in the development of [225Ac]DOTATATE therapy for progressive neuroendocrine tumors (NETs).
4. **EANM Springer Prize for Best Paper (2019):** Recognized for publishing the best paper ^{177}Lu -PSMA-617 in metastatic Castration Resistant prostate cancer (mCRPC) in the European Journal of Nuclear Medicine, this prize highlights excellence in nuclear medicine research, particularly novel approaches to treatment in patients with end-stage mCRPC.
5. **IGCDA Oration (2019):** Delivered an oration at the Metabolic Conclave 2019 in Dubai on Thyroid Cancer management, demonstrating thought leadership and influence in the fields of nuclear Oncology.
6. **Oration Award by the Indian Society of Thyroid Surgeons (2017):** Delivered an oration at a key conference, highlighting influence and expertise in the field of thyroid cancer -surgery and nuclear medicine.
7. **Prof R.D. Lele Oration (2012):** Delivered at the Annual Conference of Association of Nuclear Medicine Physicians of India, reflecting significant contributions to the advancement of nuclear medicine practices in India.
8. **Kelleresberger Memorial Oration (2005):** Awarded by the Ethiopian Medical Association at the United Nations Convention Centre in Addis Ababa, recognizing international contributions and thought leadership in nuclear medicine.
9. **Emeritus Professor N. Ramdas Award (2003):** Recognized for contributions to clinical thyroidology, highlighting breakthroughs in the treatment and research of thyroid diseases using nuclear medicine techniques.

10. **Brig. S.K. Majumdar Memorial Oration Award (2002):** Awarded by the Society of Nuclear Medicine-India for leadership and advancements in nuclear medicine research.
11. **Young Investigator Award by Indo-American Society of Nuclear Medicine (2001):** Recognition of early-career excellence, particularly innovative research in nuclear medicine presented at a global platform in Toronto, Canada.

Institute Awards

12. **AIIMS Oncology Research Award (2022):** this award was received in the field of Clinical Sciences Oncology for the new avenue of treatment of neuroendocrine tumors.
13. **AIIMS Excellence Award in Clinical Research (2021):** This accolade highlights top-tier clinical research at AIIMS, recognizing pioneering work in the management of radioiodine refractory DTC (RR-DTC) using ¹⁷⁷Lu-FAPI and its oncological applications.
14. **AIIMS Excellence Award (First Prize) in Clinical Oncology Research (2020):** This award demonstrates outstanding research contributions, specifically in clinical oncology, further establishing expertise in nuclear medicine therapies.
15. **AIIMS Excellence Research award in Clinical Research (2019):** This award demonstrates the recognition for the outstanding contribution to clinical science oncology for discovering a new cancer treatment for neuroendocrine tumor patients with targeted alpha particle therapy.
16. **AIIMS Excellence Award in Clinical Research (2017):** Recognition of exemplary research at AIIMS, emphasizing continued excellence in the field of nuclear medicine and clinical oncology.

17. AIIMS Excellence Award in Clinical Research (2015): Awarded for outstanding research contributions, emphasizing consistent excellence in clinical research over multiple years.